Skip to Content

'
Scott E. Woodman, MD, PHD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
7455 Fannin Street
Unit Number: 904
Houston, TX 77054
Room Number: 1SCR2.3022
Phone: 713-792-2921
Fax: 713-563-3424

Education & Training

Degree-Granting Education

2004 Albert Einstein College of Medicine, New York, NY, MD, Medicine
2004 Albert Einstein College of Medicine, New York, NY, PHD, Molecular Pharmacology
2000 Albert Einstein College of Medicine, New York, NY, MS, Biomedical Science
1996 Michigan State University, East Lansing, MI, MA, Philosophy
1993 Hillsdale College, Hillsdale, MI, BS, Philosophy and Biology

Postgraduate Training

2007 Medical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX
2004 Clinical Fellowship, Internal Medicine, Harvard Medical School, Boston, MA
2004 Clinical Residency, Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA

Board Certifications

2007 American Board of Internal Medicine

Honors and Awards

2012 Cancer Center Support Grant Faculty Awars, National Cancer Insitute, MD Anderson Cancer Center
2011 Rising STARS Award, University of Texas Systems
2010 Lupe C. Garcia Fellowship in Cancer Research, M. D. Anderson Cancer Center
2010 Melanoma SPORE Career Development Award, National Cancer Institute, MD Anderson Cancer Center
2010 National Eye Institute Travel Grant, Association for Research in Vision and Opthamology
2009 Merit Award, American Society for Clinical Oncology
2009 Paul Calabresi Award for Clinical Oncology, MD Anderson Cancer Center, National Institutes of Health
2009 Young Investigator Award, American Society of Clinical Oncology (ASCO)
2008 Carol Cogdell Courtney Fellowship, Melanoma Oncology, MD Anderson Cancer Center
2007 Ruth L. Kirschstein National Research Service Award, MD Anderson Cancer Center, National Institute of Health
2006-2007 Resident Teaching Award, Harvard Medical School Class of 2007
2005-2006 Outstanding Resident Teacher Award, Harvard Medical School, Shapiro Institute
2004 Alpha Omega Alpha Honor Society, Albert Einstein College of Medicine
1996-2004 Medical Scientist Training Program Grant, National Institutes Health

Professional Memberships

Alpha Omega Alpha, Honor Medical Society
Member, 6/2004
American Society of Clinical Oncology
Member, 6/2009
Association for Research in Vision and Ophthalmology
Member, 6/2010

Selected Publications

Peer-Reviewed Original Research Articles

1. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li H, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizee G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi LG, Davies MA, Hwu P. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. e-Pub 12/8/2015. PMID: 26645196.
2. Han L, Diao L, Yu S, Xu X, Li J, Zhang R, Yang Y, Werner HM, Eterovic AK, Yuan Y, Li J, Nair N, Minelli R, Tsang YH, Cheung LW, Jeong KJ, Roszik J, Ju Z, Woodman SE, Lu Y, Scott KL, Li JB, Mills GB, Liang H. The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell 28(4):515-28, 10/12/2015. e-Pub 10/1/2015. PMCID: PMC4605878.
3. Wilson MA, Zhao F, Khare S, D'Andrea K, Wubbenhorst B, Roszik J, Woodman SE, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL. Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma. Clin Cancer Res. e-Pub 8/2015. PMID: 26307133.
4. Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Res. e-Pub 7/2015. PMID: 26206558.
5. Glitza IC, Haymaker C, Bernatchez C, Vence LM, Rohlfs ML, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Woodman SE, Patel S, Hwu WJ, Radvanyi L, Davies MA, Papadopoulos NE, Hwu P. Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: A case report. Cancer Immunol Res. e-Pub 7/2015. PMID: 26216417.
6. Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, Woodman SE. Genetic Analysis of the 'Uveal Melanoma' C918 Cell Line Reveals Atypical BRAF and Common KRAS Mutations and Single Tandem Repeat Profile Identical to the Cutaneous Melanoma C8161 Cell Line. Pigment Cell Melanoma Res 28(3):357-9, 5/2015. e-Pub 3/23/2015. PMID: 25515650.
7. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E immunohistochemical expression pattern as a surrogate of BRAF mutation status in 154 patients with advanced melanoma. Hum Pathol. e-Pub 5/2015. PMID: 26058727.
8. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. J Invest Dermatol 135(2):508-15, 2/2015. e-Pub 8/22/2014. PMCID: PMC4289407.
9. Roszik J, Woodman SE. HotSpotter: efficient visualization of driver mutations. BMC Genomics 15(1). e-Pub 12/1/2014. PMID: 25435088.
10. Peng G, Woodman SE, Mills GB. RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy? Cancer Discov 4(9):988-90, 9/2014. PMCID: PMC4155513.
11. Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu WJ, Bedikian AY, Davies MA, Woodman SE, Hwu P. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma. Melanoma Res 24(4):342-8, 8/2014. PMID: 24743052.
12. Chattopadhyay C, Grimm EA, Woodman SE. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One 9(2):e83957, 2014. e-Pub 2/2014. PMCID: PMC3923717.
13. Griewank K, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, Schimming T, Livingstone E, Sucker A, Grabellus F, Metz C, Susskind D, Hillen U, Speicher MR, Woodman SE, Steuhl KP, Schadendorf D. Conjunctival Melanomas harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas. Clin Cancer Res. e-Pub 4/30/2013. PMID: 23633454.
14. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Frederick DT, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P. BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. Clin Cancer Res 19(2):393-403, 1/2013. e-Pub 11/2012. PMID: 23204132.
15. Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol 39(9):821-5, 9/2012. e-Pub 7/19/2012. PMID: 22809251.
16. Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P. Anti-tumor T cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. e-Pub 8/30/2012. PMID: 22936666.
17. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE. Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner. Clin Cancer Res. e-Pub 7/19/2012. PMID: 22733540.
18. Griewank KG, Yu X, Khalili J, Sozen MM, Stempke-Hale K, Bernatchez C, Wardell S, Bastian BC, Woodman SE. Genetic and Molecular Characterization of Uveal Melanoma Cell Lines. PIGM CELL MELANOMA R 25(2):182-7, 3/2012. e-Pub 2/2012. PMCID: PMC3288394.
19. Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer J 18(2):148-52, Mar-Apr, 3/2012. PMID: 22453016.
20. Woodman SE. BAP1tism of a Tumor Suppressor. Clin Cancer Res 18(2):323-5, 1/15/2012. e-Pub 12/2/2011. PMID: 22140212.
21. Woodman SE, Lazar AJ, Aldape KD, Davies MA. New Strategies in Melanoma: Molecular Testing in Advanced Disease. Clin Cancer Res. e-Pub 1/24/2012. PMID: 22275506.
22. Deng W, Vashisht Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. PIGM CELL MELANOMA R. e-Pub 12/2011. PMID: 22171948.
23. Patel SP, Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. DRUG DES DEV THER 5:489-95, 2011. e-Pub 12/2011. PMID: 22267918.
24. Woodman SE, Mills GB. Are oncogenes sufficient to cause human cancer? P NATL ACAD SCI USA 107(48):20599-600, 11/2010. e-Pub 11/2010. PMCID: PMC2996413.
25. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70(21):8736-47, 11/2010. e-Pub 10/2010. PMID: 20959481.
26. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80(5):568-74, 9/2010. e-Pub 5/2010. PMID: 20457136.
27. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 15(24):7538-7546, 12/2009. PMCID: PMC2805170.
28. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, Kim KB, Woodman S, Davies M, Plaza JA, Nash JW, Prieto VG, Lazar AJ, Ivan D. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22(11):1446-56, 11/2009. e-Pub 8/2009. PMID: 19718013.
29. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8):2079-85, 8/2009. e-Pub 8/2009. PMID: 19671763.
30. Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P, Medscape. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5(12):737-40, 12/2008. e-Pub 10/21/2008. PMID: 18936790.
31. De Souza AP, Cohen AW, Park DS, Woodman SE, Tang B, Gutstein DE, Factor SM, Tanowitz HB, Lisanti MP, Jelicks LA. MR imaging of caveolin gene-specific alterations in right ventricular wall thickness. Magn Reson Imaging 23(1):61-8, 1/2005. PMID: 15733789.
32. Woodman SE, Cheung MW, Tarr M, North AC, Schubert W, Lagaud G, Marks CB, Russell RG, Hassan GS, Factor SM, Christ GJ, Lisanti MP. Urogenital alterations in aged male caveolin-1 knockout mice. J Urol 171(2 Pt 1):950-7, 2/2004. PMID: 14713860.

Abstracts

1. Woodman. Genomic Classification of Cutaneous Melanoma. The Cancer Genome Atlas 161(7):1681-96, 6/2015. PMCID: PMC4580370.
2. Jason Roszik, Aron Joon, Alan Siroy, Lauren Haydu, Francesco Stingo, Veera Baladandayuthapani, Patrick Hwu, Michael Tetzlaff, Jennifer Wargo, Jie Qing Chen, Laszlo Radvanyi, Chantale Bernatchez, Jeff Gershenwald, Alexander J. Lazar, Michael A. Davies, Woodman SE. A novel algorithm applicable to cancer next generation sequencing panels accurately predicts total tumor mutation load and correlates with clinical outcomes in melanoma. 2015.
3. Kim IK, Place CS, Esmaeli B, Amin-Mansour, Lane AM, Gragoudas ES, Van Allen EM, Garraway LA, Woodman SE. Exome sequencing of primary and metastatic uveal melanoma. 2015.
4. Junna Oba, Wei-Lien Wang, Agda K. Eterovic, Clifford C. Stephan, Jason Roszik, Charuta R. Kale, Cara L. Haymaker, Mark Routbort, Lauren E. Haydu, Chantale Bernatchez, Michael A. Davies, Alexander J. F. Lazar, Elizabeth A. Grimm, Woodman SE. Global genomic and small molecule inhibitor interrogation of KIT mutant melanoma reveals underlying biology and implicates novel molecular targets. 2015.
5. Katherine G. Roth, Alan E. Siroy, Michael Tetzlaff, Jason Roszik, Funda Meric-Bernstam, Kenna R. Shaw, Gordon B. Mills, Mark Routbort, Kenneth R. Hess, Lauren E. Haydu, Jeffrey Gershenwald, Alexander Lazar, Michael Davies, Woodman SE. Mutation and clinical analysis of a large cohort of acral and mucosal melanomas. 2015.
6. Kim IK, Place CS, Esmaeli B, Amin-Mansour, Treacy D, Carter S, Hodis E, Wagle N, Seepo S, Vasquez F, Nickerson E, Cibulskis K, McKenna A, Gabriel SB, Getz G, Van Allen EM, Garraway LA, Woodman SE. Systematic genomic characterization of primary and metastatic uveal melanoma. 2015.
7. Woodman SE, Yu X, Chattopadhyay C, Williams M, Poindexter N, Jager MJ, Grimm E, Esmaeli B. GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors. International Society of Ocular Oncology International Meeting, 2011. e-Pub 11/2011.
8. Woodman SE, Yu X, Chattopadhyay C, Poindexter N, Grimm E. GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors. National Cancer Institute Translational Science Meeting, 2011. e-Pub 7/2011.
9. Woodman SE, Yu X, Chattopadhyay C, Williams M, Poindexter N, Jager MJ, Grimm E, Esmaeli B. GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors. Association for Research in Vision and Ophthalmology Annual Meeting, 2011. e-Pub 5/2011.

Book Chapters

1. Scott E. Woodman. Handbook of Targeted Cancer Therapy. In: Handbook of Targeted Cancer Therapy. In Press.
2. Kim Margolin, Vernon Sondak, Susan Swetter, Scott E. Woodman. Holland-Frei Cancer Medicine. In: Holland-Frei Cancer Medicine, 9th. In Press.
3. Scott E, Woodman MD, PhD. KIT Kinase. In: Targeted Therapy in Translational Cancer Research. In Press. ISBN: 9781118468579.

Last updated: 12/16/2015